Authors
Latest:
Discussions Swirl on the Role of PD-1 Inhibitors for Gastric/GEJ/ESCC Cancers With 1%-10% PD-L1 ExpressionNataliya Uboha, MD, PhD, and Robert Albert Anders, MD, PhD, unpack the unfavorable risk-benefit profile of PD-1 inhibitors in patients with certain PD-L1–negative gastrointestinal cancers and discussions from a recent ODAC meeting.
Latest:
Dr. Carolyn Britten on Next Steps in ImmunotherapyCarolyn D. Britten, MD, chief, Division of Hematology Oncology, associate director, Clinical Investigations, at the Hollings Cancer Center, Medical University of South Carolina, discusses questions that remain in immunotherapy.
Latest:
Dr. Lefkowits Addresses Misconceptions About Palliative Care IntegrationCarolyn Lefkowits, MD, gynecologic oncologist, and palliative care doctor, at the University of Colorado, addresses common misconceptions regarding palliative care integration.
Latest:
Back to the Bench: Exploring the Potential of CAR T-Cell Therapy in OncologyMiguel-Angel Perales, MD, and Caron A. Jacobson, MD, share insights regarding the context and implications of the recent actions by the FDA to add boxed warnings to CAR T-cell therapies.
Latest:
Dr. Langstraat on Sentinel Lymph Nodes for Endometrial CancerCarrie L. Langstraat, MD, gynecologic oncologist, Mayo Clinic, discusses the role of sentinel lymph nodes in patients with endometrial cancers.
Latest:
Carrie Stricker on the Efficacy of Survivorship Care PlansCarrie Stricker from the Abramson Cancer Center of the University of Pennsylvania on the Efficacy of Survivorship Care Plans for Posttreatment Breast Cancer Survivors.
Latest:
Dr. Anderson on Superoxide Dismutase Mimetic GC4419 in Treating Patients With Oropharyngeal CarcinomaCarryn Anderson, MD, assistant professor of Radiation Oncology, University of Iowa, discusses a phase Ib/IIa study of superoxide dismutase mimetic GC4419 to reduce chemoradiotherapy-induced oral mucositis in patients with oral cavitiy or oropharyngeal carcinoma.
Latest:
Dr. Presant on Adjusting Clinical Trials to Value-Based CareCary Presant, MD, FACP, FASCO, City of Hope Medical Center, discusses clinical trials and value-based care.
Latest:
Dr Cosgrove on the Evolution of ADC Treatment in Ovarian CancerCasey M. Cosgrove, MD, discusses the evolution of treatment with antibody-drug conjugates for patients with ovarian cancer.
Latest:
Dr. Cosgrove on Utilizing Biomarker-Informed Treatments Endometrial CancerCasey M. Cosgrove, MD, discusses utilizing biomarker-informed treatments in endometrial cancer.
Latest:
How to Perform the Perfect Bone Marrow BiopsyObtaining a high-quality bone marrow aspirate and biopsy is very important for the patient—and for you. Following these general guidelines will help you do this successfully.
Latest:
Dr. Bollard on the Treatment of EBV-Positive LymphomaCatherine Bollard, MBChB, MD, Professor of Pediatrics, Medicine, and Pathology & Immunology, Baylor College of Medicine, discusses the treatment of EBV-positive lymphoma with T-cell therapy.
Latest:
Merging Community Practices With an Academic Cancer CenterConsolidation of community oncology practices with hospital-based cancer centers is an accelerating trend that will affect future healthcare delivery models. This year, the Community Oncology Alliance reported hospital acquisitions and corporate mergers among 55% of 1338 community oncology practices surveyed, representing a 20% increase over the previous year's results.
Latest:
Dr. Diefenbach on Polatuzumab Vedotin Plus Obinutuzumab and Lenalidomide in FLCatherine M. Diefenbach, MD, discusses polatuzumab vedotin (Polivy) plus obinutuzumab (Gazyva) and lenalidomide (Revlimid) in patients with follicular lymphoma.
Latest:
Dr. Pietanza on Rova-T for Small Cell Lung CancerCatherine Pietanza, MD, assistant attending physician at Memorial Sloan Kettering Cancer Center, discusses novel targeted therapy rovalpituzumab tesirine (Rova-T), which showed activity in relapsed and refractory small cell lung cancer (SCLC) in a recent phase I study.
Latest:
Dr. Smith on Acquired Resistance to Targeted Agents for AMLCatherine Smith, MD, assistant professor, Division of Hematology/Oncology, Department of Medicine, University of California San Francisco Helen Diller Family Comprehensive Cancer Center, discusses patient acquired resistance in quizartinib (AC220) and gilteritinib (ASP2215) in acute myeloid leukemia (AML).
Latest:
More Effort Needed to Understand Value Breadth of Molecular TestingAs the use of testing increases, so does the importance of understanding exactly what it can do for your patients and how to get the most out of the results.
Latest:
How Does IT Affect Quality of Care?Oncology practices across the country are using computer technology to improve outcomes and quality of care for our patients.
Latest:
Dr. Eng on the Rationale for Studying the Impact of RAS Mutations in Early Onset Resectable CRCCathy Eng, MD, FACP, FASCO, discusses the rationale for studying the impact of RAS mutations in patients with early onset resectable colorectal cancer.
Latest:
Dr Eng on Unmet Needs Within the mCRC Treatment ParadigmCathy Eng, MD, FACP, FASCO, discusses unmet needs within the metastatic colorectal cancer treatment paradigm.
Latest:
Second-Line Treatment of mCRC: Rechallenging TherapyThe role of molecular assays, including liquid biopsies, in providing information on resistance mechanisms in metastatic colorectal cancer and the impact of testing results on decisions for rechallenging with a previous therapy.
Latest:
Audience Q&A: Best Practices in Managing HER2-Amplified CRCFielding questions from the audience, expert oncologists discuss clinical trials, molecular testing, and early-stage disease in the context of HER2-amplified colorectal cancer.
Latest:
Cecile Pizot on Breast Cancer Mortality in Latin America and AsiaCecile Pizot, biostatistician in epidemiology at the International Prevention Research Institute, discusses the changes in mortality rates in breast cancer around the world. In a study on 47 countries, 39 saw breast cancer mortality rates decline, but mortality rates were on the rise in Latin American and Asian countries.
